Trial Profile

A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC Extension

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixoberogene soroparvovec (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions
Acronyms OPTIC-EXT
Sponsors Adverum Biotechnologies

Most Recent Events

10 Feb 2026 Timeframe for primary endpoint has been changed from 156 weeks to 416 weeks.
10 Feb 2026 Planned End Date changed from 1 Jun 2025 to 26 Jun 2030.
10 Feb 2026 Planned primary completion date changed from 1 Jun 2025 to 26 Jun 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com